Table 1.
Selected public-private population genomic screening initiatives
| Project | Collaborators | Target population | Year initiated | Assay | Results returned |
|---|---|---|---|---|---|
| Geisinger MyCodea | Regeneron Pharmaceuticals | Geisinger patients | 2014 | Exome | 60+ genes for actionable disorders |
| Renown Healthy Nevadab | 23andMe Helix |
Nevada residents | 2016 2018 |
Array Exome |
Ancestry + health Ancestry + traits |
| Sanford Imageneticsc | Illumina | Sanford patients | 2018 | Array | 59 genes for actionable disorders, pharmacogenomics |
| NorthShore DNA-10Kd | Color | NorthShore patients | 2019 | Genome | Cancer, cardiac, pharmacogenomics |
| Mayo Clinice | Regeneron Pharmaceuticals | Mayo Clinic patients | 2019g | Exome | Planning to research |
| Intermountain HerediGene: Population Studyf | deCODE Genetics/Amgen | Utah and Idaho residents | 2019g | Genome | Planned |
bhealthynv.org/
cimagenetics.sanfordhealth.org/sanford-chip/
dnorthshore.org/personalized-medicine/our-services/color-genetics-test/
egenomeweb.com/genetic-research/regeneron-mayo-ink-pact-sequence-genotype-100k-patient-samples
fintermountainhealthcare.org/heredigene
gNot yet enrolling patients.